Corporate Action2 Nov 2026, 11:20 pm
India Glycols subsidiary Ennature Bio Pharma gets listing approval
AI Summary
India Glycols Ltd announced that its subsidiary, Ennature Bio Pharma Limited (EBL), has received listing and trading approvals from BSE and NSE on November 2, 2026. This approval is for the issuance and allotment of 2,23,42,255 equity shares of Rs. 5/- each. Trading is set to commence on November 4, 2026. This development follows observation letters received from the stock exchanges regarding a Scheme of Arrangement and material updates communicated by EBL.
Key Highlights
- Ennature Bio Pharma Limited (EBL) received listing and trading approvals.
- Approvals granted by BSE and NSE on November 2, 2026.
- 2,23,42,255 equity shares of Rs. 5/- each to be listed.
- Trading to commence on November 4, 2026.
- Development relates to a Scheme of Arrangement.
Price Impact
More from INDIAGLYCO